08 jun: Colombian Stocks Decline, Led By Ecopetrol; Peso Weakens
09 jun: RBS Chairman: Issues in Restructuring Talks Include Convertible C..
08-06-2012 23:55:00

J&J to Record $600 Million Charge in 2Q

Relateret indhold

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:55 ET (21:55 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/middag: Regnskaber sender Nordea og Tryg til tops

28-01-2015 11:39:25
Finanssektoren sætter et stort fingeraftryk på det danske aktiemarked onsdag. Nydelige regnskaber fra Nordea og Tryg belønnes med store kursstigninger i et mark..

Tryg slår markedets forventninger med flere længder

28-01-2015 08:03:55
Tryg kom betydeligt bedre ud af fjerde kvartal af 2014 end ventet af analytikerne.Det viser regnskabet fra forsikringskoncernen onsdag morgen.Nettoresultatet la..

Intermail Q1: Overskud fordoblet trods dræn på toplinjen

27-01-2015 16:33:34
Intermail, der blandt andet producerer konvolutter, havde trods fortsat faldende omsætning overskud i første kvartal af det forskudte regnskabsår 2014/15.- I fø..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Nordea Q4: Øger overskud og udbytte
2
Tirsdagens aktier: FLSmidth gravet ned da rekordrusen stoppede
3
Apple overgik enhver forventning i seneste kvartal
4
FLS/Sydbank: Endnu intet lys for enden af tunnelen
5
Tryg slår markedets forventninger med flere længder

Relaterede aktiekurser

Johnson & Johnson 102,09 0,0% Aktiekurs uændret
Omnicare Inc 76,15 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. januar 2015 13:08:15
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150121.1 - EUROWEB5 - 2015-01-28 13:08:15 - 2015-01-28 13:08:15 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x